BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 37499326)

  • 1. Exosomal PD-L1 derived from head and neck squamous cell carcinoma promotes immune evasion by activating the positive feedback loop of activated regulatory T cell-M2 macrophage.
    Wei F; Fang R; Lyu K; Liao J; Long Y; Yang J; Wen W; Sun W
    Oral Oncol; 2023 Oct; 145():106532. PubMed ID: 37499326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma.
    Sun W; Wei FQ; Li WJ; Wei JW; Zhong H; Wen YH; Lei WB; Chen L; Li H; Lin HQ; Iqbal M; Wen WP
    Br J Cancer; 2017 Nov; 117(11):1631-1643. PubMed ID: 28949956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoplasmic reticulum stress promotes the release of exosomal PD-L1 from head and neck cancer cells and facilitates M2 macrophage polarization.
    Yuan Y; Jiao P; Wang Z; Chen M; Du H; Xu L; Xu J; Dai Y; Wu FG; Zhang Y; Wu H
    Cell Commun Signal; 2022 Jan; 20(1):12. PubMed ID: 35090495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. M1 macrophages induce PD-L1
    Wu J; Pang X; Yang X; Zhang M; Chen B; Fan H; Wang H; Yu X; Tang Y; Liang X
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38148114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E3 Ubiquitin Ligase RNF125 Suppresses Immune Escape in Head and Neck Squamous Cell Carcinoma by Regulating PD-L1 Expression.
    Jiang C; He L; Xiao S; Wu W; Zhao Q; Liu F
    Mol Biotechnol; 2023 Jun; 65(6):891-903. PubMed ID: 36344734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between spatial distribution of leukocyte subsets and clinical presentation of head and neck squamous cell carcinoma.
    Netzer C; von Arps-Aubert V; Mačinković I; von der Grün J; Küffer S; Ströbel P; von Knethen A; Weigert A; Beutner D
    Front Immunol; 2023; 14():1240394. PubMed ID: 38322012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
    Mao L; Xiao Y; Yang QC; Yang SC; Yang LL; Sun ZJ
    Oral Oncol; 2021 Oct; 121():105472. PubMed ID: 34333450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of PD-L1
    Theodoraki MN; Yerneni SS; Hoffmann TK; Gooding WE; Whiteside TL
    Clin Cancer Res; 2018 Feb; 24(4):896-905. PubMed ID: 29233903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
    Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation of plasma-derived exosomes into CD3
    Theodoraki MN; Hoffmann TK; Whiteside TL
    Clin Exp Immunol; 2018 Jun; 192(3):271-283. PubMed ID: 29431869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4
    Franken A; Bila M; Mechels A; Kint S; Van Dessel J; Pomella V; Vanuytven S; Philips G; Bricard O; Xiong J; Boeckx B; Hatse S; Van Brussel T; Schepers R; Van Aerde C; Geurs S; Vandecaveye V; Hauben E; Vander Poorten V; Verbandt S; Vandereyken K; Qian J; Tejpar S; Voet T; Clement PM; Lambrechts D
    Immunity; 2024 Mar; 57(3):541-558.e7. PubMed ID: 38442708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.